Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133705 | 0.86 | L3MBTL1 (0.40) | L3MBTL1KAT6A | |
| SCHEMBL20129738 | 0.86 | L3MBTL1 (0.40) | L3MBTL1KAT6A | |
| SCHEMBL22187861 | 0.75 | — | — | |
| SCHEMBL20073207 | 0.73 | L3MBTL1 (0.42) | L3MBTL1 | |
| SCHEMBL20129598 | 0.69 | L3MBTL1 (0.41) | KEAP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20129596 | 0.69 | L3MBTL1 (0.41) | KEAP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20129739 | 0.69 | CA1 (0.44) | L3MBTL1 | |
| SCHEMBL22221866 | 0.67 | SLC6A2 (0.38) | KDM4EMEN1KMT2ACNR2 | |
| SCHEMBL23139059 | 0.67 | GABRA1 (0.39) | KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL22187863 | 0.65 | ACHE (0.43) | KEAP1MEN1KMT2AKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | KEAP1 863/4885KDM4E 253/4885MEN1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.